XML 99 R16.htm IDEA: XBRL DOCUMENT
v3.19.3

Intangible Assets | 9 Months Ended
--- | ---
Sep. 30, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract] |
Intangible Assets | INTANGIBLE ASSETS The following table summarizes our intangible assets, net (in millions):
|  | September 30, 2019 |  | December 31, 2018
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (4,078 | ) |  | $ | — |  |  | $ | 6,642 |  |  | $ | 10,720 |  |  | $ | (3,554 | ) |  | $ | — |  |  | $ | 7,166 |
Intangible asset - axicabtagene ciloleucel (DLBCL) |  | 6,200 |  |  | (675 | ) |  | — |  |  | 5,525 |  |  | 6,200 |  |  | (416 | ) |  | — |  |  | 5,784 |
Intangible asset - Ranexa |  | 688 |  |  | (688 | ) |  | — |  |  | — |  |  | 688 |  |  | (678 | ) |  | — |  |  | 10 |
Other |  | 1,098 |  |  | (434 | ) |  | (7 | ) |  | 657 |  |  | 1,096 |  |  | (359 | ) |  | (3 | ) |  | 734 |
Total finite-lived assets |  | 18,706 |  |  | (5,875 | ) |  | (7 | ) |  | 12,824 |  |  | 18,704 |  |  | (5,007 | ) |  | (3 | ) |  | 13,694 |
Indefinite-lived assets - in process research & development |  | 2,047 |  |  | — |  |  | (7 | ) |  | 2,040 |  |  | 2,047 |  |  | — |  |  | (3 | ) |  | 2,044 |
Total intangible assets |  | $ | 20,753 |  |  | $ | (5,875 | ) |  | $ | (14 | ) |  | $ | 14,864 |  |  | $ | 20,751 |  |  | $ | (5,007 | ) |  | $ | (6 | ) |  | $ | 15,738 |
Aggregate amortization expense related to finite-lived intangible assets was $281 million and $868 million for the three and nine months ended September 30, 2019, respectively, and $301 million and $902 million for the three and nine months ended September 30, 2018, respectively, and was primarily included in Cost of goods sold on our Condensed Consolidated Statements of Operations. The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of September 30, 2019 (in millions):
Fiscal Year |  | Amount
2019 (remaining three months) |  | $ | 281 |
2020 |  | 1,125 |
2021 |  | 1,124 |
2022 |  | 1,124 |
2023 |  | 1,124 |
Thereafter |  | 8,046 |
Total |  | $ | 12,824 |

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration